Genmab A/S (GMAB) News
Track canonical SquawkNews coverage tagged to GMAB, Genmab A/S. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 16 indexed stories across 9 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
GMAB: Late-stage pipeline advances and strong growth set up major Q4 data readouts in oncology
Multiple late-stage assets are advancing, with six new phase III trials and strong financial growth. Petosemtamab and EPKINLY are poised for major data readouts in Q4, potentially setting new standards in head and neck,
NEWS | Sep 15, 2026, 02:08 PM UTC
L
GMAB: Late-stage pipeline advances and strong financials set up multiple key data readouts in Q4
Significant pipeline progress includes nine revenue-generating medicines, six new phase III trials, and strong financial growth. Petosemtamab and EPKINLY are advancing in late-stage trials, with multiple data readouts ex
EARNINGS | Sep 15, 2026, 01:32 PM UTC
L
Weekly Recap: Epcoritamab Phase III readout and DKK 44.3m share issuance
Genmab A/S Sponsored ADR (OMXCOP:GMAB) said a pivotal Phase III readout for epcoritamab in first-line DLBCL is due next quarter while the company issued 28,011 new shares after employee warrant exercises, raising ~DKK 44
EQUITY | Sep 14, 2026, 05:15 AM UTC
L
GMAB: Three key phase III oncology readouts are imminent, targeting major commercial opportunities
Three major phase III readouts are expected next quarter, including pivotal data for epcoritamab in first-line DLBCL, petosemtamab in head and neck cancer, and Rina-S in PROC. Epcoritamab and petosemtamab are positioned
EQUITY | Sep 09, 2026, 09:55 PM UTC
L
GMAB: Major phase III data for three assets expected next quarter, targeting broad first-line markets
Three major phase III assets are set for key data readouts next quarter, with epcoritamab, petosemtamab, and Rina-S targeting significant first-line and expansion opportunities. Epcoritamab's label updates and new indica
EQUITY | Sep 09, 2026, 08:18 PM UTC
L
Genmab to increase share capital via employee warrant exercise
Genmab A/S will increase its share capital by 28,011 shares following the exercise of employee warrants. The increase will be effected without preemption rights for existing shareholders or others.
EQUITY | Sep 08, 2026, 06:47 PM UTC
L
Genmab to convene extraordinary general meeting on Oct 7, 2026
Genmab A/S will convene an Extraordinary General Meeting on Wednesday, October 7, 2026, at 3:00 PM CEST at its offices on Carl Jacobsens Vej 30, 2500 Valby, Denmark.
EQUITY | Sep 08, 2026, 10:07 AM UTC
L
Genmab Raises FY2026 Sales Guidance from $4.065B-$4.395B to $4.325B-$4.525B vs $4.355B Est
Genmab (NASDAQ: GMAB ) raises FY2026 sales outlook from $4.065 billion-$4.395 billion to $4.325 billion-$4.525 billion vs $4.355 billion estimate.
EARNINGS | Aug 06, 2026, 07:52 PM UTC
H
CoreWeave upgraded, IBM initiated: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled. Top 5 Upgrades: Truist upgraded CoreWeave (CRWV) t
MNA | Jul 22, 2026, 01:46 PM UTC
L
GMAB upgraded from Hold to Buy W/ $43 PT (from $32) @ TDCowen
GMAB upgraded from Hold to Buy W/ $43 PT (from $32) @ TDCowen
EQUITY | Jul 22, 2026, 12:19 PM UTC
L
GMAB Upgrade from Hold to Buy W/$43.00 PT (from $32.00) at TD Cowen
GMAB Upgrade from Hold to Buy W/$43.00 PT (from $32.00) at TD Cowen
EQUITY | Jul 22, 2026, 12:02 PM UTC
L
GMAB Genmab announces net sales of darzalex® (daratumumab) for second quarter of 2026 Genmab - net sales of darzalex in Q2 of 2026 totaled U
GMAB Genmab announces net sales of darzalex® (daratumumab) for second quarter of 2026 Genmab - net sales of darzalex in Q2 of 2026 totaled USD 4,207M - Q2 darzalex net trade sales were USD 2,435M in U.S. and USD 1,772M i
FX | Jul 15, 2026, 10:23 AM UTC
L
HC Wainwright & Co. Maintains Buy on Genmab, Raises Price Target to $40
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Genmab (NASDAQ: GMAB ) with a Buy and raises the price target from $38 to $40.
EQUITY | Jul 02, 2026, 11:05 AM UTC
L
Genmab/AbbVie Lymphoma Trial Meets Main Goal, Analyst Eyes Bigger Market Opportunity
Genmab A/S – ADR (NASDAQ: GMAB ) on Monday shared topline results from the Phase 3 EPCORE DLBCL-4 trial. The trial evaluated the combination of fixed-duration epcoritamab and lenalidomide, compared to standard-of-care, r
EARNINGS | Jun 30, 2026, 04:31 PM UTC
H
Select Premarket Movers
Upside: -AVAV +35% (earnings, guidance) -VWAV +29% (acquires 51% controlling interest in private Israeli aerospace and defense company Meteor Aerospace for ~$20.4M in stock) -SEDG +11% (solar stock strength following FCC
GEOPOLITICS | Jun 30, 2026, 12:26 PM UTC
H
Market-Moving News for June 30th
AVAV: 31% | AeroVironment shares are trading higher after the company reported better-than-expected Q4 financial results. GMAB: 8% | Genmab shares are trading higher after the company announced topline results from the P
EARNINGS | Jun 30, 2026, 11:13 AM UTC